AB0974 ANALYSIS OF DYSLIPIDEMIA IN SYSTEMIC LUPUS ERYTHEMATOSUS. (2nd June 2020)

• Record Type: Journal Article
• Authors: Chen, A. S. H.; Lee, J. H.; Ya-Chiao, H.; Yu, H. H.; Wang, L. C.; Lin, Y. T.; Yang, Y. H.; Chiang, B. L.
• Is Part Of: Annals of the rheumatic diseases. Volume 79(2020)Supplement 1
• Page Start: 1782
• Page End: 1782
• Publication Date: 2020-06-02
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2020-eular.5742
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Systemic lupus erythematosus (SLE) is an autoimmune disease and is characterized by multiple autoantibodies associated with a multisystem illness. However, studies of dyslipidemia in pediatric SLE patients are limited. Objectives: The aim of our study is to describe the lipid profiles associated with disease activity and organ damage and their correlation with laboratory parameters in pediatric SLE patients. Methods: We retrospectively reviewed medical records from a single tertiary hospital in Taipei, Taiwan from 2002 to 2018. One hundred and twenty-four patients diagnosed with SLE were included. Dyslipidemia is defined as elevations in total cholesterol (TC), low-density lipoprotein (LDL), and triglyceride (TG) levels, and a reduction in high-density lipoprotein (HDL) levels. We gathered all of the lipid profiles, clinical characteristics, and laboratory parameters from each patient. Pediatric SLE patients participated in this study, based on their lipid profile, were classified as dyslipidemic or not. The mean values of each evaluated parameters were calculated and analyzed with generalized estimating equation (GEE) method. Results: Total thirty-one SLE patients were enrolled; twenty-four (77%) patients had dyslipidemia. The levels of total cholesterol, TG, and LDL in the dyslipidemic group are significantly higher than those of non-dyslipidemia (214.0 mg/dL vs 145.0 mg/dL, 130.1 mg/dL vs 76.4 mg/dL, 138.7 mg/dL vs 82.0 mg/dL; respectively). The mean values of white blood cell count (6726/µL) in dyslipidemia group are significantly higher than non-dyslipidemia group (4521/µL; p =0.0157). In contrast, the level of high-sensitivity CRP in the non-dyslipidemia group (0.2 mg/dL) are significantly lower than those of patients with dyslipidemia (0.49 mg/dL; p =0.0486). Conclusion: It has been well known that CRP could suppress HDL and increase TG and that elevation of CRP might indicate increased cardiovascular risk. Our results demonstrated that elevated high sensitivity CRP levels were noted in SLE patients with dyslipidemia. It is suggested that routine monitoring of cardiovascular risk factors, such as dyslipidemia, should be recommended for pediatric SLE patients. References: [1]Szabó, M.Z., Szodoray, P. & Kiss, E. Immunol Res (2017) 65: 543. [2]Atta, A.M., Silva, J.P.C.G., Santiago, M.B. et al. Clin Rheumatol (2018) 37: 1539. [3]Yu, H.H., Chen, P.C., Yang, Y.H. Atherosclerosis. 2015; 243(1): 11–18. Acknowledgments: The authors acknowledge statistical assistance provided by the Center of Statistical Consultation and Research in the Department of Medical Research, National Taiwan University Hospital Disclosure of Interests: None declared